1263W94. Antiviral

Drugs of the Future

Volumn 22, Issue 7, 1997, Pages 707-710

  Graul, A ^a   Tracy, M ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; GANCICLOVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; RAT; SHORT SURVEY;

EID: 0030791194     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.07.414586     Document Type: Short Survey

References (12)

1. Chamberlain, S.D., Koszalka, G.W. (The Wellcome Found, Ltd.). Therapeutic cpds. EP 769017, WO 9601833.
2. Tong, L., Qian, C., Massariol, M.-J., Bonneau, P.R., Cordingley, M.G., Lagacé, L. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 1996, 383: 272-5.
3. Qiu, X., Culp, J.S., DiLella, A.G., Hellmig, B., Hoog, S.S., Janson, C.A., Smith, W.W., Abdel-Meguid, S.S. Unique fold and active site in cytomegalovirus protease. Nature 1996, 383: 275-9.
4. Shieh, H.-S., Kurumbail, R.G., Stevens, A.M. et al. Three-dimensional structure of human cytomegalovirus protease. Nature 1996, 383: 279-82.
5. Chamberlain, S.D., Chan, J.H., Tidwell, J.H., Peckham, G.E., Harvey, R.J., Dornsife, R.E., Frick, L.W., Townsend, L.B., Drach, J.C., Koszalka, G.W. Synthesis and evaluation of a series of carbohydrate modified derivatives of the anti-HCMV agent, 5,6-dichloro - 2 - isopropylamino - 1 - (β - L - ribofuranosyl) - 1H - benzimidazole (1263W94). 213th ACS Natl Meet (April 13-17, San Francisco) 1997, Abst CARB 022.
6. Biron, K.K., Davis, M.G., Stanat, S.C., Walton, L.M., Smith, A., Koszalka, G.W., Drach, J.C., Townsend, L.B., Harvey, R.J. Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst H85.
7. Koszalka, G.W., Chamberlain, S.D., Harvey, R.J., Frick, L.W., Good, S.S., Davis, M.L., Smith, A., Drach, J.C., Townsend, L.B., Biron, K.K. Benzimidazoles for the treatment of human cytomegalovirus. Antivir Res 1996, 30(1): Abst 85.
8. Investigational compound shows promise against cytomegalovirus (CMV) in preliminary studies. Glaxo Wellcome, Inc. Press Release 1996, September 18.
9. Zacny, V.L., Davis, M.G., Biron, K.K., Pagano, J.S. Activity of benzimidazole riboside 1263W94 (5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H -benzimidazole) against Epstein-Barr virus. Antivir Res 1997, 34(2): Abst 156.
10. Frick, L.W., Hsieh, A.Y., Good, S.S. Pharmacokinetics and metabolism in rats and monkeys of 1263W94, a potent and selective inhibitor of human cytomegalovirus. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst H27.
11. Wang, L.H., Lyogendran, S., Weller, S., Sallabank, P., Wiggs, R., Bye, A. A phase I trial evaluating the tolerability and pharmacokinetics (PK) of 1263W94 following single oral administration of escalating doses in normal healthy volunteers. 36th Intersci Conf Antimicrob Agents Chemother (Sept 15-18, New Orleans) 1996, Abst H28.
12. Wang, L.H., Peck, R., Chan, P.Q., Youle, M., Eaves, J., Bye, A. A phase I tolerability and pharmacokinetic (PK) trial of 1263W94, a novel anti-HCMV agent, in HIV-infected volunteers. 4th Conf Retroviruses Opportunistic Infect (Jan 22-26, Washington DC) 1997, Abst.